MULTI TUMOR-ASSOCIATED ANTIGEN (MULTITAA) CELL THERAPY

Heterogeneous Tumor  Multiple Targeted Antigen  Epitope Spreading  Complete Tumor Elimination

MultiTAA T Cells  Multi-target Approach  Recruitment of Endogenous Immunity  Natural Long T Cell Persistence

PETER L. HOANG, PRESIDENT & CEO:
“Compared to today’s leading CAR-T and TCR Therapies, our T cell platform is:

- Highly efficacious and extremely durable, without the need for lymphodepletion;
- Non gene-modified, enabling significantly reduced manufacturing cost/complexity;
- Significantly less toxic than CAR-T with virtually no toxicity or CRS;
- Multi-antigen specific, compares to CAR-T which target a single epitope/antigen;
- Capable of driving an endogenous immune response through ‘epitope spreading’;
- Capable of addressing patients currently inaccessible to CAR-T therapies.”

MANUFACTURING PROCESS

SUPERIOR EFFICACY AND TOXICITY VERSUS CAR-T/TCR

- Comparable or Superior Efficacy vs. CAR-T Therapies
- Superior Durability of Response
- No Significant Toxicities Associated with Therapy to Date
- Costs 80-90% Less to Manufacture Compares to CAR-T/TCR
ADRESSES MAJOR LIMITATIONS OF CAR-T & TCR APPROACHES

- **MULTI-SPECIFIC**: None
- **EPITOPE SPREADING**: None
- **NO GENETIC MODIFICATION**: None
- **NO FATALITIES CAUSED BY THERAPY**: None
- **NO LYMPHOCYTE DEPLETION REQUIRED**: None
- **TREATMENT COST**: 
  - JCAR017 & JCAR017 estimated price $250,000
  - YESCARTA estimated price $373,000
  - UCART19 estimated price $200,000
  - NY-ESO-1 TCR estimated price $250,000
  - KYMRIAH estimated price $475,000
- **COMMON ISSUES IN COMPETITIVE CELL THERAPIES**: 
  - INCONSISTENT RESPONSE RATES
  - SIGNIFICANT RELAPSE RATES
  - HIGH TOXICITY
  - LIMITED EFFICACY IN SOLID TUMORS
  - HIGH MANUFACTURING COSTS
  - DIFFICULT TO SCALE
  - POTENTIAL TO ADDRESS MAJOR ISSUES WITH OTHER CELL THERAPIES

1. Based on Wall Street Research Estimates